KOSUNI CRYPTO
Korea's Crypto Pulse, in English
$BTC $ETH $XRP $SOL $DOGE
News
Bullish

Moderna Surpasses AI Stocks in S&P 500 Gains, Up 663% This Year

Published October 11, 2026 8:17 AM · 5 views $MRNA
Moderna Surpasses AI Stocks in S&P 500 Gains, Up 663% This Year

AI hype drove the stock market in 2026. However, the top performer in the S&P 500 this year is not a chip manufacturer but a coronavirus vaccine maker, which rose 663% to $225 as of Friday's close.

This surge is based on unconfirmed results from an ongoing cancer vaccine clinical trial. Just by mid-August, the company's stock had fallen nearly 90% from pandemic highs.

Why Moderna Outpaced AI Stocks

The company behind the widely known coronavirus vaccines is Moderna (MRNA). On August 19, Moderna and Merck announced that their experimental cancer vaccine had passed its final-stage clinical trial for skin cancer patients.

This news came after a difficult period. Coronavirus vaccine sales dropped sharply, leading Moderna to lay off over 800 employees last year.

The stock surged 177% on the announcement but fell 24% the next day. According to Inquirer, BeInCrypto had already noted in June that Moderna's rebound for 2026 was imminent after a flu vaccine approval led to a 125% rise.

On Friday, the upward trend continued as Moderna was added back to the Nasdaq-100 index (which includes the largest non-financial companies on Nasdaq).

Nasdaq reports that over 200 funds managing more than $80 billion must buy the stock, which explains the surge. On the same day, The New York Times reported plans for a national cancer vaccine initiative starting in December, pushing Moderna shares up 14%.

Moderna's stock performance. Source: Yahoo Finance

AI-related stocks are not far behind. SanDisk, which sells memory chips to AI data centers, rose 566% this year as demand for AI memory chips grew. The S&P 500 gained about 14%.

The Critical October 24th

So far, Moderna and Merck have revealed the vaccine's effectiveness but not specific figures. Investors will learn all details at a major cancer conference in Madrid on October 24.

Notably, not all investors are joining the rally. Former pharmaceutical executive Martin Shkreli believes Moderna's stock bubble will burst within six months.

Moderna's current market capitalization is approximately $89.8 billion. Competitors BioNTech and Genentech are also testing their own cancer vaccines.

Korean Source

This article is an English localization of a Korean-language crypto news report. Original headline: S&P500 코로나 백신주, 올해 600% 상승